SCHEMBL345282

SCHEMBL345282

CCOC(=O)C=C(c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.51
HDAC4 P56524 3/20 0.51
HDAC1 Q13547 3/20 0.51
HDAC7 Q8WUI4 3/20 0.51
HDAC2 Q92769 3/20 0.51
HDAC10 Q969S8 3/20 0.51
HDAC11 Q96DB2 3/20 0.51
HDAC8 Q9BY41 3/20 0.51
HDAC6 Q9UBN7 3/20 0.51
HDAC9 Q9UKV0 3/20 0.51
HDAC5 Q9UQL6 3/20 0.51
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13264797 0.94 MAPT (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4389151 0.94 CES2 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4389147 0.94 CES2 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13236826 0.89 ALDH1A1 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13236835 0.89 CYP1A1 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11891940 0.85 ALDH1A1 (0.54) MAPTALDH1A1KDM4EHPGDMEN1
SCHEMBL11296722 0.85 ALDH1A1 (0.54) MAPTALDH1A1KDM4EHPGDMEN1
SCHEMBL11296725 0.85 ALDH1A1 (0.54) MAPTALDH1A1KDM4EHPGDMEN1
SCHEMBL2207899 0.85 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2207897 0.85 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2847784-B1 POLISHING PAD WITH LIGHT-STABLE LIGHT-TRANSMITTING REGION CABOT MICROELECTRONICS CORP (US) 2017-07-05 EP claimed
US-9156125-B2 Polishing pad with light-stable light-transmitting region CABOT MICROELECTRONICS CORPORATION (US) 2015-10-13 US claimed
US-20130273813-A1 POLISHING PAD WITH LIGHT-STABLE LIGHT-TRANSMITTING REGION CABOT MICROELECTRONICS CORPORATION (US) 2013-10-17 US claimed
EP-1100447-B1 SUNSCREEN COMPOSITIONS PROCTER & GAMBLE (US) 2004-05-12 EP claimed
EP-1100447-A1 SUNSCREEN COMPOSITIONS The Procter & Gamble Company (US) 2001-05-23 EP claimed
WO-2000006110-A1 SUNSCREEN COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-02-10 WO claimed
US-5989528-A Sunscreen compositions THE PROCTER & GAMBLE COMPANY (US) 1999-11-23 US claimed
US-5587150-A Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate L'OREAL (FR) 1996-12-24 US claimed
US-5576354-A Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate L'OREAL (FR) 1996-11-19 US claimed
EP-0514491-B1 LIGHT-RESISTANT FILTERING COSMETIC COMPOSITION CONTAINING A UV-A FILTER AND AN ALKYL BETA, BETA-DIPHENYLACRYLATE OR AN ALKYL ALPHA-CYANO-BETA, BETA-DIPHENYLACRYLATE OREAL (FR) 1993-11-03 EP claimed
EP-3134499-B1 CLEANING FORMULATIONS FOR CHEMICALLY SENSITIVE INDIVIDUALS: COMPOSITIONS AND METHODS VAN BUSKIRK GREGORY (US) 2025-01-29 EP disclosed
US-20240254411-A1 Alkyl Polyglycoside-Containing Cleaning Formulations for Chemically Sensitive Individuals SENSITIVE HOME, INC. (US) 2024-08-01 US disclosed
US-12004630-B2 System for dispensing a cosmetic product L'OREAL (FR) 2024-06-11 US disclosed
US-11998104-B2 System for dispensing a cosmetic product L'OREAL (FR) 2024-06-04 US disclosed
US-11980277-B2 System for dispensing a cosmetic product L'OREAL (FR) 2024-05-14 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11980277-B2 System for dispensing a cosmetic product PDE12, SAMM50, POLR1C HDAC3 4639/4885HDAC4 2232/4885HDAC1 3648/4885
US-11998104-B2 System for dispensing a cosmetic product PDE12, SAMM50, POLR1C HDAC3 4639/4885HDAC4 2232/4885HDAC1 3648/4885
US-12004630-B2 System for dispensing a cosmetic product PDE12, SAMM50, POLR1C HDAC3 4639/4885HDAC4 2232/4885HDAC1 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.